Theranexus: THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS
Lyon, France – June 9, 2022 – 6:00 p.m. CEST – Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today its participation in several scientific and business events including the Forum of the Federation of European Societies de Neurosciences (FENS), the Batten Disease Support and Research Association (BDSRA) conference and the BIO international convention which will be held in June and July 2022.
Theranexus will present at Organic International Convention which will bring together more than 15,000 life sciences stakeholders from more than 70 countries from June 13 to 19, 2022 in San Diego in the United States. The company will have the advantage of speaking during a face-to-face session, which will allow Theranexus to present its latest innovations and meet companies as part of its strategic development approach.
Julien Veys, Chief Business Development Officer of Theranexus said: “I am delighted to be able to share with other professionals in the sector the company’s new strategic direction and its strengths in the field of rare neurological diseases on Tuesday June 14 at 11 a.m. during the International Convention BIO, the largest convention in ‘business in our sector bringing together all the international players in the pharmaceutical and biopharmaceutical industry”.
In addition, Theranexus will be present at Federation of European Neuroscience Societies – Forum FENS 2022, from July 9 to 13, 2022 in Paris and presenting the latest innovations from its NeuroLead platform, in collaboration with the French Atomic Energy and Alternative Energies Commission (CEA) and the Collège de France:
- The first presentation “Text mining to select drug candidates in orphan indications: an application to neuronal ceroid lipofuscinoses” will address the bioinformatics approaches used in the search for drug candidates targeting orphan indications,
- The second presentation titled “In Vitro Model of Astrocytes-Neurons Interactions at the Synapse for Drug Discovery Using Human Induced Pluripotent Stem Cells” will focus on the cellular model of neuron-astrocytes interactions in drug discovery new drug candidates,
- Finally, the third presentation “Functional studies of neuron-astrocyte interactions in vivo” will address some of the preclinical measurement tools available for neuron-astrocyte interactions.
Theranexus will also present the progress of its Batten-1 clinical program in Batten disease at the Batten Disease Support and Research Association (BDSRA) Annual Conference to be held in Cleveland, Ohio July 8-10, 2022.
Finally, Theranexus gave a presentation entitled “Pharmacological modulation of brain connectivity and visual response in a pathological rat model revealed by functional ultrasound imaging” at Functional Ultrasound Imaging of the Brain Conference – fUSbrain 2022 – which was held in Corsica at the beginning of June, and took part in the annual scientific conference of the Rare Diseases Foundation at the Collège de France on May 31, presenting the company and its assets.
Mathieu Charvériat, Deputy Managing Director and Scientific Director concluded: “These various presentations highlight both the advances of our drug candidate Batten-1 in clinical application for Batten disease and the discovery of new drug candidates with our NeuroLead platform in the field of rare neurological diseases. These presentations give us the opportunity to strengthen our visibility and connection with academic and industrial players and patient associations and confirm the remarkable dynamism and recognition of the scientific merits of our R&D teams.”.
Next financial publication:
tuesday july 12: Cash position as of June 30, 2022
Theranexus is an innovative biopharmaceutical company spun off from the Commissariat aux Energies Alternatives et à l’Energie Atomique (CEA). She specializes in the treatment of central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.
Theranexus has a unique platform for the identification and characterization of advanced therapies focused on rare neurological disorders and a first drug candidate in clinical development for Batten disease.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259-ALTHX).
Presentation at the Bio Convention on Tuesday, June 14 at 11 a.m. PST in Room 1
© 2022 NewsNews